TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$HIMS · "Hims Will be a $2,000 Stock By 2030"
now playing · $HIMS
$HIMS···bullish· high· posantonio linares
Hims partners with Novo Nordisk to become central healthcare data network
The Novo partnership validates Hims' platform model; as GLP-1 peptides commoditize, value shifts to networks holding longitudinal patient data that can personalize therapies, crea…
$NVO···bullish· mediumantonio linares
Novo Nordisk partners with Hims to access longitudinal patient data for personalized GLP-1 delivery
Novo is behind Lilly in next-generation GLP-1s and recognizes the need for patient data to differentiate its peptides; partnering with Hims gives them distribution and data access…
$LLY···neutral· mediumantonio linares
Eli Lilly leads in next-gen GLP-1s but faces commoditization pressure
Lilly is ahead with GLP-3/retatrutide but all peptide sequences are becoming commodities, forcing price competition for distribution; they may eventually need to join data platfor…
$REGN···bullish· lowantonio linares
Regeneron's mesenchymal cell therapies could leverage Hims platform for personalization
Regeneron's pipeline including mesenchymal cells represents the type of next-gen biotech that will need longitudinal patient data platforms to personalize delivery and compete eff…
$IBRX···bullish· lowantonio linares
ImmunityBio seen as future joiner to Hims data platform for personalized cell therapies
Next-generation biotech companies like ImmunityBio will have increasing incentives to join Hims' platform to leverage its longitudinal patient data for personalizing cell therapie…